AKT1 and neoplasm: We found that low-doses VEGFR2-TKI with YS-49 increased tumor size slightly, while the tumor from high-dose with Copanlisib group was significantly reduced, indicating that inhibiting the PI3K-AKT signaling pathway could reverse tumor resistance induced by high-dose treatment (Figure 3F).